Amarin Corp Plc (AMRN): Practice Update STORY OF THE WEEK Publi...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	15
Posts	697
Boards Moderated	0
Alias Born	10/03/2017

dogn

Re: None

Thursday, 04/04/2024 9:49:05 PM

Thursday, April 04, 2024 9:49:05 PM

Practice Update STORY OF THE WEEK
Published in Cardiology
Journal Scan / Research · April 03, 2024
Lp(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl
Journal of the American College of Cardiology
TAKE-HOME MESSAGE

This post hoc analysis of a large, randomized, placebo-controlled trial (REDUCE-IT) evaluated the use of icosapent ethyl (IPE; an active form of omega-3 and the generic form of Vascepa) in reducing the risk of major adverse cardiovascular events (MACE) across a range of lipoprotein(a) (Lp[a]) levels. The authors found that IPE therapy reduced the risk of MACE in all patients, including those with clinically relevant elevated Lp(a) levels.
Lp(a) is a common genetic variant of lipoprotein that elevates MACE risk despite statin therapy and LDL-C control. This study suggests a role for IPE therapy in lowering the risk of MACE in this population, who otherwise has limited treatment options.
– Timothy Overton, MD, MPH

https://www.practiceupdate.com/content/lpa-blood-levels-and-cardiovascular-risk-reduction-with-icosapent-ethyl/164034